Pharma downplays 25% tariff impact: US healthcare could feel the blow instead of India—what sector experts say
India’s pharmaceutical industry is holding a cautiously optimistic view in the face of the United States’ proposed 25% import tariff on a range of Indian drug products. While the initial reaction across industries was concern over potential disruption, the pharma sector appears to be downplaying the direct impact of these tariffs. Industry leaders and policy…